Výsledky vyhledávání - "David Sarfati-Mizrahi"

Akademický článek

Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

IntroductionSeveral effective vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and implemented in the population. However, the current production capacity falls short of meeting global demand. Therefore, i

Externí odkaz: https://doaj.org/article/f59adc9f44cc4bf6920104dbbb786afe

Zobrazit plný text záznamu

Akademický článek

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

Publikováno v: npj Vaccines, Vol 8, Iss 1, Pp 1-14 (2023)

Abstract There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a

Externí odkaz: https://doaj.org/article/d2ac0c69327549fb9217708e2039498c

Zobrazit plný text záznamu

Akademický článek

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

Autor: Jesús Horacio Lara-Puente, Juan Manuel Carreño, Weina Sun, Alejandro Suárez-Martínez, Luis Ramírez-Martínez, Francisco Quezada-Monroy, Georgina Paz-De la Rosa, Rosalía Vigueras-Moreno, Gagandeep Singh, Oscar Rojas-Martínez, Héctor Elías Chagoya-Cortés, David Sarfati-Mizrahi, Ernesto Soto-Priante, Constantino López-Macías, Florian Krammer, Felipa Castro-Peralta, Peter Palese, Adolfo García-Sastre, Bernardo Lozano-Dubernard

Publikováno v: mBio, Vol 12, Iss 5 (2021)

Several highly efficacious vaccines for SARS-CoV-2 have been developed and are used in the population. However, the current production capacity cannot meet the global demand. Therefore, additional vaccines—especially ones that can be produced local

Externí odkaz: https://doaj.org/article/d47ce303ae344529b5dda46a5d3fc757

Zobrazit plný text záznamu

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico

Publikováno v: medRxiv

There is still a need for safe, efficient and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live reco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bde479e654e6ef0648aed025d62266a
https://pubmed.ncbi.nlm.nih.gov/35169806

Zobrazit plný text záznamu

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

Autor: David Sarfati-Mizrahi, Bernardo Lozano-Dubernard, Héctor Elías Chagoya-Cortés, Rosalía Vigueras-Moreno, Peter Palese, Florian Krammer, Constantino López-Macías, Oscar Rojas-Martínez, Francisco Quezada-Monroy, Felipa Castro-Peralta, Juan Manuel Carreño, Ernesto Soto-Priante, Adolfo García-Sastre, Weina Sun, Alejandro Suárez-Martínez, Gagandeep Singh, Luis Ramírez-Martínez, Georgina Paz-De la Rosa, Jesus Horacio Lara-Puente

Publikováno v: mBio, Vol 12, Iss 5 (2021)
mBio

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed in record time and show excellent efficacy and effectiveness against coronavirus disease 2019 (COVID-19). However, currently approved vaccines cannot meet th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc345961fcf6785368dd7a1928cfd35e
https://journals.asm.org/doi/10.1128/mBio.01908-21

Zobrazit plný text záznamu

Protection and differentiation of infected from vaccinated animals by an inactivated recombinant Newcastle disease virus/avian influenza H5 vaccine

Autor: David Sarfati-Mizrahi, Manuel Joaquin Gay-Gutierrez, Elizabeth Loza-Rubio, Ricardo Flores-Castro, Ernesto Soto-Priante, Felipa Castro-Peralta, Bernardo Lozano-Dubernard

Publikováno v: Avian diseases. 54

Specific-pathogen-free chickens immunized at 14 days of age with either an inactivated recombinant Newcastle disease virus-LaSota/avian influenza H5 (K-rNDV-LS/AI-H5) vaccine or a killed Newcastle disease/avian influenza whole-virus vaccine (K-ND/AI)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2474b5857d8cc5535bebc8bfbdc0c64f
https://pubmed.ncbi.nlm.nih.gov/20521639

Zobrazit plný text záznamu

Protective Dose of a Recombinant Newcastle Disease Lasota–Avian Influenza Virus H5 Vaccine Against H5N2 Highly Pathogenic Avian Influenza Virus and Velogenic Viscerotropic Newcastle Disease Virus in Broilers with High Maternal Antibody Levels

Autor: Bernardo Lozano-Dubernard, Ernesto Soto-Priante, Manuel Joaquin Gay-Gutierrez, Ricardo Flores-Castro, David Sarfati-Mizrahi, Felipa Castro-Peralta, Elizabeth Loza-Rubio

Publikováno v: Avian Diseases Digest. 5:e21-e22

The protective dose of a live recombinant LaSota Newcastle disease virus (NDV)-avian influenza H5 vaccine (rNDV-LS/AI-H5) was determined in broiler chickens with high levels of maternal antibodies against NDV and avian influenza virus (AIV). At hatch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d549c125fd1cdc17f7e6269905d1655
https://doi.org/10.1637/9126-873509-digest.1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání